

Haematologica
HAEMATOL/2019/229013
Version 4

The CRISPR/Cas9-mediated gene deletion efficiently retards the progression of Philadelphia-positive acute lymphoblastic leukemia in a p210 BCR-ABL1^{T315I mutation} mouse model

Yu-Ting Tan, Lin Ye, Fei Xie, Jiaming Wang, Markus Müschen, Sai-Juan Chen, Yuet Wai Kan, and Han Liu

Disclosures: 1. This work was supported by the National Key Research and Development Program of China 2018YFA0107802 (to H.L.), Shanghai Sailing Program 19YF1429500 (to Y.-T.T.), the National Natural Science Foundation of China 81900107 (to Y.-T.T.) and 81973996 (to H.L.), NIH Grant P01DK088760 (to Y.W.K.), the Program for Breakthrough Biomedical Research award (to Y.W.K.), which was partially funded by the Sandler Foundation, the Program of Shanghai Academic/Technology Research Leader 19XD1402500 (to H.L.), the Shanghai Municipal Health Commission 2019CXJQ01 (to S.-J.C.), the Shanghai Municipal Education Commission Gaofeng Clinical Medicine Grant (to S.-J.C. and H.L.), the Collaborative Innovation Center of Hematology (to S.-J.C. and H.L.), and the Samuel Waxman Cancer Research Foundation (to S.-J.C. and H.L.). M.M. is a Faculty Scholar of the Howard Hughes Medical Institute (HHMI) and supported by an Outstanding Investigator Award from NCI (R35CA197628). Y.-T.T. was awarded a scholarship under the State Scholarship Fund from China Scholarship Council. We thank Lars Klemm for the instructions on mouse transplantation experiments, and we also thank Ferid Chehab and Marcus Muench for their spirited discussions. 2. N/A 3. N/A

Contributions: Y.-T.T. performed most of the experiments. L.Y. assisted with the construction of plasmid vectors and mouse transplantation experiments. F.X. and J.W. assisted with the cell culture experiments. M.M. provided the patient-derived xenografts. Y.-T.T., Y.W.K., H.L., and S.-J.C. conceived the project. Y.-T.T., H.L., Y.W.K., and S.-J.C. were the principal investigators. Y.-T.T., H.L., Y.W.K., and S.-J.C. wrote the manuscript.